CSF3 and neoplasm: Similarly, a study by Shojaei et al. (19) revealed the preferential expression of G-CSF in refractory tumors and that treatment with anti-G-CSF antibody significantly reduces circulating and tumor-associated MDSCs, delays growth and inhibits tumor angiogenesis via Bv8 blockade (19).